TILHIGH SIGNALRISK10-K

TIL has undergone a fundamental business transformation, shifting from a clinical-stage biopharmaceutical company focused on bispecific antibody development to an entity with substantially reduced R&D operations and no clear business description.

The complete removal of all language describing TIL's biopharmaceutical operations, drug pipeline, and strategic partnerships suggests either a major business pivot or potential exit from the biotech sector. The replacement with generic forward-looking statement boilerplate indicates management may be preparing for significant strategic changes or restructuring that could materially impact shareholder value.

Comparing 2026-03-27 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

The financial statements reflect this operational shift with R&D expenses substantially reduced from $141.1M to $39.6M, while current assets grew meaningfully to $191.4M despite declining stockholders' equity. Operating cash flow improved to -$36.6M from -$55.7M, and current liabilities decreased significantly, suggesting the company may be winding down research operations and preserving cash for alternative strategic purposes.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
-71.9%
$141.1M$39.6M

R&D spending cut 71.9% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
+53.8%
$124.5M$191.4M

Current assets grew 53.8% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
-38.7%
$7.9M$4.8M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Cash Flow
Cash Flow
+34.3%
-$55.7M-$36.6M

Operating cash flow surged 34.3% — exceptional cash generation, highest quality earnings signal.

Stockholders Equity
Balance Sheet
-32.8%
$169.4M$113.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
-24.6%
$8.8M$6.6M

Cash decreased 24.6% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
-22.8%
$263.6M$203.5M

Total assets contracted 22.8% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-04
ADDED
All statements, other than statements of historical facts, contained in this Annual Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, and objectives of management, are forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as may, will, should, would, expect, plan, anticipate, could, might, intend, target, ongoing, project, estimate, believe, estimate, predict, potential or continue or the negative of these terms or other similar expressions intended to identify statements about the future.
These statements speak only as of the date of this Annual Report and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements.
We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations.
You should read this Annual Report and the documents that we have filed as exhibits to this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect.
Risk Factor Summary Investing in our securities involves a high degree of risk.
Below is a summary of material factors that make an investment in our securities speculative or risky.
Importantly, this summary does not address every aspect of our risk factors, all of the risks that we face, or other factors not presently known to us or that we currently believe are immaterial.
Additional discussion of the risks summarized in this Risk Factor Summary, as well as other risks that we face, can be found under the heading Risk Factors in Part I of this Annual Report.
These risks include, among others, the following: We have incurred significant losses since our inception and have identified an indicator of substantial doubt about our ability to continue as a going concern.
REMOVED
Overview We are a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies.
We are advancing the development of our lead product candidate, AXN-2510/IMM2510, a bispecific antibody targeting both programmed death-ligand 1, or PD-L1, and vascular endothelial growth factor, or VEGF, in solid tumor cancers, and we seek to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need.
(formerly SynBioTx, Inc.), or Axion Bio, in-licensed certain bispecific antibodies, including AXN-2510 (formerly SYN-2510)/IMM2510 and AXN-27M (formerly SYN-27M)/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4, from ImmuneOnco Biopharmaceuticals (Shanghai) Inc., or ImmuneOnco.
AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers.
Pursuant to the license and collaboration agreement with ImmuneOnco, or the IO Collaboration Agreement, Axion Bio has an exclusive license to research, develop, manufacture and commercialize these product candidates globally, including in the United States, Europe and Japan, excluding mainland China, Hong Kong, Macau and Taiwan, or Greater China.
ImmuneOnco retains development and commercialization rights in Greater China.
ImmuneOnco is conducting a Phase 1 open label trial in China of AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors that have failed prior therapies, including triple-negative breast cancer, or TNBC, squamous non-small cell lung cancer (squamous NSCLC), hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors including soft tissue sarcomas and thymic cancer.
As of January 13, 2025, ImmuneOnco announced over 100 patients have been enrolled with AXN-2510/IMM2510 in this clinical trial.
The preliminary data reported by ImmuneOnco in the 2024 ASCO abstract as of December 21, 2023 showed: 33 patients had received IMM2510 at 9 dose levels (0.007-20.0 mg/kg), the median age was 57 years (range 36-74), the median prior line of therapy was 3 (range 1-13), and 27.3% patients received prior anti PD-1/PD-L1 inhibitor therapies.
Treatment-related adverse events (TRAEs) occurred in 32 patients (97.0%).
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →